Comments :

georgia    on Jul 21, 2010 Says : General comments The abstract has clarity of definition and strikes to the point.The introduction clearely shows to the raader what the article is about.I believe that after reading the manuscript or the presentacion, the researchers will be to investigate futher in the filed of epigenetic mechanisms.The bibliograpfy is ample and satisfactory.Finally I strongly believe that the medical world will benefit aftert viewing this presentacion. Kind regards Dr Gerontara Georgia

georgia    on Jul 21, 2010 Says : This presentation is a systematic and accurate view of epigenetic changes in multiple myeloma. The tasks of the text have a reasonable order and provide the information and needed explanations in conjunction with selected bibliography. This review highlights the possible role of epigenetic therapy in plasma cell malignancy according to recent findings. This global study of the genetic aberrations may facilitate the assessment of clinical course of the disease and the application of novel therapeutic modalities in future. It could be a valuable mention for scholars, physicians and researchers in the attempt of establishing the precise methylation profile, detecting minimal residual disease and using epigenetically targeted therapy. Matsis K. Director Haematologist nosopam@otenet.gr

georgia    on Jul 21, 2010 Says : Thiw presentation is a systematic and accurate view of epigenetic changes in MM.The tasks of the text have a reasonable order ana provide the information ana needed expanations in conjunction with selected bibliography.Thi review highlighits the possible role of epigenetic therapy in plasma cvell malignancy according to recent fimdings.This global study of the genetic abnerrations may facilitate the assessment of clinical course of the disease and the application of novel therapeutic modalities in future.It could be a valuable mention for scholars,physicians and researchers in the attempt af establishing the precise methylation profile,detecting minimal residual disease and using epigenetically targeted therapy. Matsis K. Director

Reference : References 1.Hallek M, Bergsagel PL, Anderson KC. Multiple Myeloma: increasing evidence for multi    more

Reference : References 1.Hallek M, Bergsagel PL, Anderson KC. Multiple Myeloma: increasing evidence for multistep transformation process. Blood. 1998;3-21. 2.Bergsagel PL, Kuehl WM, Chromosome translocations in multiple myeloma. Oncogene. 2001;20:5611-5622. 3.Takashashi T, Shivapurkar N, Reddy J, et al. DNA methylation profiles of disea lymphoid and hematopoietic malignancies. Clin Cancer Res 2004;10:2928-35. 4.Ng MH, Chung YF, Lo KW, Wickham NW, Lee JC, Huang DP. Frequent hypermethylation of p16 genes and p15 genes in multiple myeloma. Blood. 1997;89:2500-2506. 5.Katzenllenbogen RA, Baylin SB, Herman JG, Hypermethylation of DAP-kinae CpG island is a common alteration in B-cell malignancies. Blood. 1999;93:4347-4353. 6.Galm O, Yoshikawa H, Esteller M, Osieka R, Herman JG, SOCS-1 a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood. 2003;101:2784-2788. 7.Chim CS, Pang R, Fung TK, Choi CL, Liang R. Epigenetic dysrerulation of Wnt signaling pathway in multiple myeloma 8.Mateos MV, Garcia-Sanz R, Lopez-Perez R, et al. Methylation is an inactivating mechanism of p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br J Haematol 2002;118:1034-40. 9.Ng MH, To KW, Lo KW, et al Frequent death associated protein kinase promoter hypermethylation in multiple myeloma. Clin Cancer Res 2001;7:1724-9. 10. Ng MH, Death associated protein kinase: from regulation of apoptosis to tumor suppressive functions and B cell malignancies. Apoptosis 2002;7:261-70. 11.Pompeia C, Hodge DR, Plass C, et al Microarray analysis of epigenetic silencing of gene expression in the KAS-6/1 multiple myeloma cell line. Cancer Res 2004;64:3465-73. 12Galm O, Yoshikawa H, Esteller M, Osieka R, Herman JG. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 2003;101:2784-8. 13.Chim CS, Kwong YL, Fung TK, Liang R. Methylation profiling in multiple myeloma. Leuk Res 2004;28:379-85. 14.Hodge DR, Peng B, Cherry JC, et al. Interleukin-6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res 2005;65:4673:-82. 15.Catley L, Weisberg E, Kiziltepe T, et al. Aggresome induction by proteoasome inhibitor bortezomib and a-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells Blood 2006;108:3441-9. 16.Maiso P, Carvahal-Vergara X, Ocio EM, et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006;66:5781-9. 17. Mitsiades CS, Mitisades NS, McMullan CJ, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 2004;101:540-5. 18.Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apotosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2004;10:3839-52. 19.Weber M, Hellmann I, Stadler MB, Ramos L, Pddbo S, Rebhan M, Sch?beler D (2007) Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 39:457–466 20. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis:epigenetics joins genetics. Trends Genet 2000;16 : 168-74 21.Legube, G., and Trouche, D. (2003). Regulating histone acetyltransferases and deacetylases. EMBO Rep 4, 944-947. 22.Taunton, J., Hassig, C. A., and Schreiber, S. L. (1996). A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272, 408-411. 23. Brownell, J. E., and Allis, C. D. (1996). Special HATs for special occasions: linking histone acetylation to chromatin assembly and gene activation. Curr Opin Genet Dev6, 176-184. 24.Chen, H., Tini, M., and Evans, R. M. (2001). HATs on and beyond chromatin. Curr Opin Cell Biol 13, 218-224. 25.Cosma, M.P. , Tanaka, T. and Nasmyth , K. 1999. Ordrered requitment of transcription and chromatin remodeling factors to a cell cycle and developmentally regulated promoter. Cell: 299-311 26.Esteller M.Profiling aberrant DNA methylation in hematologic neoplasmas:a view from the tip of the iceberg.Clin Immunol 2003; 109:80-8. 27. Andrian Bird DNA methylation patterns and epigenetic memory Genes Dev. 2002 Jan 1;16(1):6-21 28.Baylin SB(2002).Mechanisms ubderlying epigenetically mediated gene silencing in ancer.Semin Cancer Biol ;12:331-337 29.Nishioka, K., Chuikov, S., Sarma, K., Erdjument-Bromage, H., Allis, C. D., Tempst, P., and Reinberg, D. (2002). Set9, a novel histone H3 methyltransferase that facilitates transcription by precluding histone tail modifications required for heterochromatin formation. Genes Dev 16, 479-489. 30.Ruiz-Carrillo, A., Wangh, L. J., and Allfrey, V. G. (1975). Processing of newly synthesized histone molecules. Science 190, 117-128. 31.Taunton, J., Hassig, C. A., and Schreiber, S. L. (1996). A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272, 408-411 32.Thiagalingam, S., Cheng, K. H., Lee, H. J., Mineva, N., Thiagalingam, A., and Ponte, J. F. (2003). Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci 983, 84-100. 33.Allis, C. D., Chicoine, L. G., Richman, R., and Schulman, I. G. (1985). Depositionrelated histone acetylation in micronuclei of conjugating Tetrahymena. Proc Natl Acad Sci U S A 82, 8048-8052. 34.Ruiz-Carrillo, A., Wangh, L. J., and Allfrey, V. G. (1975). Processing of newly synthesized histone molecules. Science 190, 117-128. 35.Kleff, S., Andrulis, E. D., Anderson, C. W., and Sternglanz, R. (1995). Identification of a gene encoding a yeast histone H4 acetyltransferase. J Biol Chem 270, 24674- 24677. 36.Allis, C. D., Chicoine, L. G., Richman, R., and Schulman, I. G. (1985). Depositionrelated histone acetylation in micronuclei of conjugating Tetrahymena. Proc Natl Acad Sci U S A 82, 8048-8052. 37.Parthun, M. R., Widom, J., and Gottschling, D. E. (1996). The major cytoplasmic histone acetyltransferase in yeast: links to chromatin replication and histone metabolism. Cell 87, 85-94. 38.Kaufman, P. D., Kobayashi, R., Kessler, N., and Stillman, B. (1995). The p150 and p60 subunits of chromatin assembly factor I: a molecular link between newly synthesized histones and DNA replication. Cell 81, 1105-1114. 39.Borrow, J., Stanton, V. P., Jr., Andresen, J. M., Becher, R., Behm, F. G., Chaganti, R. S., Civin, C. I., Disteche, C., Dube, I., Frischauf, A. M., et al. (1996). The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet 14, 33-41. 40.Neuwald, A. F., and Landsman, D. (1997). GCN5-related histone N-acetyltransferases belong to a diverse superfamily that includes the yeast SPT10 protein. Trends Biochem Sci 22, 154-155. 41.Mizzen, C. A., Yang, X. J., Kokubo, T., Brownell, J. E., Bannister, A. J., Owen- Hughes, T., Workman, J., Wang, L., Berger, S. L., Kouzarides, T., et al. (1996). The TAF(II)250 subunit of TFIID has histone acetyltransferase activity. Cell 87, 1261- 1270. 42.Chen, H., Tini, M., and Evans, R. M. (2001). HATs on and beyond chromatin. Curr Opin Cell Biol 13, 218-224. 43.Aggerholm A,Holm MS,Guldberg P,Ol;essen LH,Hokland P.Promoter hypermethylation of p 15INK4B,HIC1,CDH1,and ER is frequent in myelodyspastic syndrome and predicts poor prognosis in early-stage patients.Eur J Haematol 2006;76:23-32. 44.Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J. R., Cole, P. A., Casero, R. A., and Shi, Y. (2004). Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119, 941-953. 45.Cuthbert, G. L., Daujat, S., Snowden, A. W., Erdjument-Bromage, H., Hagiwara, T., Yamada, M., Schneider, R., Gregory, P. D., Tempst, P., Bannister, A. J., and Kouzarides, T. (2004). Histone deimination antagonizes arginine methylation. Cell 118, 545-553. 46.Wang, Y., Wysocka, J., Sayegh, J., Lee, Y. H., Perlin, J. R., Leonelli, L., Sonbuchner, L. S., McDonald, C. H., Cook, R. G., Dou, Y., et al. (2004). Human PAD4 regulates histone arginine methylation levels via demethylimination. Science 306, 279-283. 47.Bernstein, B. E., Humphrey, E. L., Erlich, R. L., Schneider, R., Bouman, P., Liu, J. S., Kouzarides, T., and Schreiber, S. L. (2002). Methylation of histone H3 Lys 4 in coding regions of active genes. Proc Natl Acad Sci U S A 99, 8695-8700. 48.Sims, R. J., 3rd, Nishioka, K., and Reinberg, D. (2003). Histone lysine methylation: a signature for chromatin function. Trends Genet 19, 629-639. 49.Lubbert M.Gene silencing of the p15/INK4B cell-cycle inhibitor by hypermethylation:an early or later epigenetic alteration in myelodysplastic syndromes? Leukemia 2003;17 :1762-4 50.Feng, Q., Wang, H., Ng, H. H., Erdjument-Bromage, H., Tempst, P., Struhl, K., and Zhang, Y. (2002). Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr Biol 12, 1052-1058. 51.Jenuwein, T. (2001). Re-SET-ting heterochromatin by histone methyltransferases. Trends Cell Biol 11, 266-273. 52. Freiman, R. N., and Tjian, R. (2003). Regulating the regulators: lysine modifications make their mark. Cell 112, 11-17. 53.Milne, T. A., Briggs, S. D., Brock, H. W., Martin, M. E., Gibbs, D., Allis, C. D., and Hess, J. L. (2002). MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell 10, 1107-1117 54.Nakamura, T., Mori, T., Tada, S., Krajewski, W., Rozovskaia, T., Wassell, R., Dubois, G., Mazo, A., Croce, C. M., and Canaani, E. (2002). ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell 10, 1119-1128. 55.Wysocka, J., Myers, M. P., Laherty, C. D., Eisenman, R. N., and Herr, W. (2003). Human Sin3 deacetylase and trithorax-related Set1/Ash2 histone H3-K4 methyltransferase are tethered together selectively by the cell-proliferation factor HCF-1. Genes Dev 17, 896-911. 56.Hamamoto, R., Furukawa, Y., Morita, M., Iimura, Y., Silva, F. P., Li, M., Yagyu, R., and Nakamura, Y. (2004). SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol 6, 731-740. 57..Hatzis, P., and Talianidis, I. (2002). Dynamics of enhancer-promoter communication during differentiation-induced gene activation. Mol Cell 10, 1467-1477. 58.Gregory WM, Richards MA, Malpas JS. Combination chemptherapy versus melphalan and prednisolone in the treatment of multiple myeloma:an overview of published trails. J. Clin Oncol 1992; 10:334-342. 59Alexanian R., Dimopoulos M. The treatment of multiple myeloma. N. Engl J Med 1994; 330:484-489. 60.D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91:4082:4085. 61Kenyon BM, Browne F, D’Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997; 64:971-978. 62.Ribatti D, Vacca A, Nico B, Quondamatteo F, Ria R, Minishcetti M et al. Bone marrow angiogenesis and mast cell density increase stimultaneously with progression of human multiple myeloma. Br J Cancer 1999; 79;451-455. 63.Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Sylvestris F et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994; 82:503-508. 64Vacca A, Di Loreto M, Ribatti D, Di Stefano R, Gadeleta-Cldarola G, Iodise G et al. Bone marrow of parents with active multiple myeloma:angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44. Am J Hematol 1995; 50:9-14. 65.Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565-1571. 66.Klausner JD, Freedman VH, Kaplan G. Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use. Clin Immunol Immunopathol 1996; 81:219-223. 67.Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173:699-703. 68.Corral LG, Muller GW, Moreira AL, Chen Y, Wu M, Strirling D et al. Selection of novel analogs of thalidomide with enchanced tumor necrosis factor alpha inhibitory activity. Mol Med 1996; 2: 506-515. 69.Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes preferentially inducing proliferation, cytokine production, and cytoxic responses in the CD8+ subset. J Exp Med 1998; 187:1885-1892. 70Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996; 31:213-21. 71.Karp JE, Broder S: Molecular foundations of cancer: New targets for intervention. Nature Med 1:309, 1995. 72.Serrano M, Hannon GJ, Beach D: A new regulation motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704, 1993. 73.Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple myeloma human cancers. Nature 368: 753, 1994 74.Kamp A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many types. Science 264:436, 1994. 75.Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, Wilson JKV, Kinzler KW, Vogelstein B: Deletion of p16 and p15 gene in brain tumors. Cancer Res 54:6353, 1994. 76.Herman JG, Jen J, Merlo A, Baylin SB: Hypermethylation associated inactivation indicates a tumor suppressor role for p15INK4B1 . Cancer Res 55:2039, 1995. 77.Lo KW, Huang DP, Lau KM: p16 gene alterations in naopharyngeal carcinoma. Cancer Res 55:2039, 1995. 78.Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D:5 CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTSI in human cancers. Nature Med 1:686, 1995. 79.Herman JG, Merlo A, Mao L, Lapiduc RG, Issa JPJ, Davidson NE,, Sidransky D, Baylin SB: Inactivation of the CDKN2/p16/MTSI/ gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55:4525, 1995. 80.Lo KW, Cheung ST, Leung SF, van Hasselt A, Tsang YS, Mak KF, Chung YF, Woo JKS, Lee JCK, Huang DP: Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res 56:2721, 1996. 81.Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, Jones PA: Methylation of the 5 CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55:4531, 1995. 82.Piacibello W, Severino A, Stacchini A, Aglietta M: Differetial effect of transforming growth factor ß1 on the proliferation of human lymphoid and myeloid leukaimia cells. Haematologica 76:460, 1991. 83.Thomson NL, Flanders KC, Smith JM, Ellingsworth LR, Roberts AB, Sporn MB: Expression of transforming growth factor-ß1 in specific cells and tissues of adult and neonatal mice. J Cell Biol 108:661, 1989. 84.Cozzolino F, Torcia M, Aldinucci D, et al. Production of interleukin-1 by bone marrow myeloma cells. Blood 1989; 74:380-387. 85.Kawano M, Tanaka H, Ishikawa H, et al. Interleukin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma. Blood 1989; 73:2145-2148. 86.Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias. J Clin Invest. 1989; 84:2008-2011. 87.Garrett IR, Durie BGM, Nedwin GE, et al. Production of bone-resorbing cytokine lymphotoxin by cultured human myeloma cells. N Engl J Med.1987; 317:526-532. 88Kiss TL, Lipton JH, Bergsagel DE, et al. Determination of IL-6, IL-1 and IL-4 the plasma of patients with multiple myeloma. Leuk Lymph. 1994; 14:335-340. 89.Lictenstein A, Berenson J, Norman D, Chang MP, Carlile A. Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood 1989; 74:1266-1273. 90.Lust JA, Donovan KA. Novel therapeutic strategies. Vlth International Workshop on Multiple Myeloma Syllabus. 1997. 91.Alsina M, Boynce B, Devlin R, et al. Development of an in vivo model of human multiple myeloma bone disease. B    less

Abstract : Abstract Multiple Myeloma (MM) is a malignant hematological disease that is characterized by clona    more

Abstract : Abstract Multiple Myeloma (MM) is a malignant hematological disease that is characterized by clonal expansion of malignant plasma cells/plasmablasts in the bone marrow (BM). MM is a very heterogenous disease, and MM cells are dependent on the BM microenvironment for survival, growth, and diferetiation1. A few partner genes have been identified as primary, nonrandom translocation partners2.Multiple genetic aberrations are observed during the pathogenesis of MM3.Two major interactive epigenetic modifications that result in a changed transcriptional activity are: (a) DNA methylation of cytosine bases within a CpG dinucleotide and (b) posttranscriptional histone modifications To what extent epigenetic changes occur in MM is not known. For a few genes, e.g., cell cycle regulators p15INK4B and p16INK4A, death-associated protein kinase, suppressor of cytokine signaling 1, and genes in the Wnt pathway, promoter hypermethylation has been shown to occur in 20% to 40% of MM patients4-7. However, a comprenhesive picture of the aberrant methylation in MM, and an understanding of how DNA methylation may contribute to the pathogenesis of MM are still lacking. In MM, hypermethylation of genes including p15,p16, DAP-kinase, BAD, BAK, BAX, BIK, SOCS-1, and E-Cadherin, has been reported 8-13. Moreover, the growth factor interleikin-6 has been implicated in processes regulating epigenetic gene silencing in MM14. Furthermore, histone deacetylase inhibitors (HDACi) have been shown to decrease survival of human MM cells in vitro by affecting genes involved in cell cycle and cell death pathways and by potentiating other proapoptotic agents 15-18. In a proposed mechanism, methylated CpG islands attract a protein, MeCP2, which recruits a transcriptional inhibitory complex that includes histone deacetylases. The deacetylated lysine tails of the histones closely interact with DNA, resulting in a transcriptionally repressed chromatin with inhibited gene transcription, providing potential synergy between demethylating drugs and histone deacetylase inhibitors. Based on the knowledge of epigenetic mechanisms, the potential application of demethylating agents should be further investigated. Multiple Myeloma remains an incurable disease, so new treatment strategies are needed to improve the outcome of patients. Key words :Myltiple Myeloma,epigenetics,HATS,HDACS,HMTs, lysine - Slides    less